OncoC4 is excited to announce that its investigational antibody, Cesalatamig, has received FDA Fast Track designation for treating advanced lung cancer, highlighting progress in cancer therapy.

Cesalatamig is Currently Being Evaluated in Phase 1/2 Studies in the United States (NCT06635785) and in China (CTR20253261) Fast Track Designation Supports Expedited Development of Cesalatamig for Non-small Cell Lung Cancer (NSCLC) that Progressed after Concurrent or Sequential PD-(L)1-targeted Immunotherapy and Platinum-based Chemotherapy ROCKVILLE, Md., Sept. 16, 2026 /PRNewswire/ — OncoC4 Inc., a late clinical-stage biopharmaceutical company […]